The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy (Q38192017)

30 August 2017

1 reference

title

The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy (English)

1 reference

30 August 2017

1 reference

2

Per Eystein Lonning

1 reference

30 August 2017

3

Hans Petter Eikesdal

1 reference

30 August 2017

1

Eilin Austreid

1 reference

30 August 2017

language of work or name

English

0 references

publication date

28 February 2014

1 reference

Expert Opinion on Pharmacotherapy

30 August 2017

published in

1 reference

30 August 2017

volume

15

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

681-700

1 reference

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Biological determinants of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Three decades of P-gp inhibitors: skimming through several generations and scaffolds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

ErbB receptors and signaling pathways in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Role of HER2/HER3 co-receptor in breast carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Tackling the diversity of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

EGFR signaling and drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Simultaneous targeting of estrogen receptor and HER2 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Breast cancer: the upgraded role of HER-3 and HER-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

The PTEN-PI3K pathway: of feedbacks and cross-talks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

PI3K‐independent AKT activation in cancers: A treasure trove for novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

mTOR inhibitors in advanced breast cancer: ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death--proliferative and anti-apoptotic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Pharmacodynamic Modeling of Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Anticancer Effects of Metformin and Its Potential Use as a Therapeutic Agent for Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Metformin Decreases the Dose of Chemotherapy for Prolonging Tumor Remission in Mouse Xenografts Involving Multiple Cancer Cell Types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Doxorubicin enhances nucleosome turnover around promoters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Molecular pathways: targeting hsp90--who benefits and who does not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Significance of ER–Src axis in hormonal therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Src: a potential target for the treatment of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Discordant cellular response to presurgical letrozole in bilateral synchronous ER breast cancers with a KRAS mutation or FGFR1 gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Tumor vasculature: the Achilles' heel of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Therapeutic targets in triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Notch signalling in cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Targeting the hedgehog pathway to mitigate treatment resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

The promise of combining inhibition of PI3K and PARP as cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Targeted therapies for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Neoadjuvant therapy as a platform for drug development and approval in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Reply to M. Gallén et al and R.S. Midgley et al.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Appropriate design of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Eag1: an emerging oncological target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

The life history of 21 breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor-Treated ER-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.2014.885952

10.1517/14656566.2014.885952

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference